Treatment of recalcitrant atopic dermatitis with omalizumab - 09/08/11
Doi : 10.1016/j.jaad.2005.09.030
Joshua E. Lane, MD a, ⁎ 
, Jason M. Cheyney, PA a, Tanda N. Lane, MD b, David E. Kent, MD a, David J. Cohen, MD a
, Jason M. Cheyney, PA a, Tanda N. Lane, MD b, David E. Kent, MD a, David J. Cohen, MD a a From the Division of Dermatology, Department of Internal Medicine, Mercer University School of Medicine, Macon
b Department of Dermatology, Emory University School of Medicine, Atlanta
Reprint requests: Joshua E. Lane, MD, Division of Dermatology, Department of Internal Medicine, Mercer University School of Medicine, 308 Hospital Dr, Suite 200, Macon, GA 31217.Macon and Atlanta, Georgia
Abstract |
Atopic dermatitis is a common diagnosis that presents a therapeutic challenge. Although multiple therapeutic modalities exist, there is no single monotherapy that has proven exceptional in ameliorating the symptoms of this disease. Current topical and systemic therapeutic options offer benefit but carry varying degrees of adverse effects that often limit their application. We present 3 patients with severe, recalcitrant atopic dermatitis successfully treated with omalizumab.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. |
|
| Disclosure: Dr Cohen is an advisor and speaker for Genentech. Published online November 25, 2005. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 1
P. 68-72 - janvier 2006 Retour au numéro
Article précédent
- Hair induction after laser-assisted hair removal and its treatment
- Paraskevas Kontoes, Spiros Vlachos, Marayiannis Konstantinos, Loupatatzi Anastasia, Savva Myrto
- Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris
- James J. Leyden, Lincoln Krochmal, Alex Yaroshinsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?